摘要
目的探讨内质网应激在罗哌卡因诱导SH-SY5Y细胞凋亡中的作用。方法罗哌卡因组采用3 mmol/L罗哌卡因处理SH-SY5Y细胞,阻断组采用10μmol/L SB203580及3 mmol/L罗哌卡因处理SH-SY5Y细胞。分析各组细胞增殖活性、凋亡,活性氧簇(ROS)及p38MAPK水平。结果与对照组比较,细胞存活率罗哌卡因组显著降低(t=5.29,P<0.05),阻断组较罗哌卡因组显著升高,但显著低于对照组(t=3.18,t=4.96,P<0.05);罗哌卡因组细胞凋亡率较对照组及阻断组显著升高(F=125.16,P<0.05);罗哌卡因组细胞内的ROS水平显著升高(P<0.05),阻断组ROS水平较对照组高(P<0.05)但显著低于罗哌卡因组(P<0.05);各组p38MAPK水平差异无统计学意义(P>0.05),罗哌卡因组p-p38MAPK显著升高,阻断后表达水平降低(P<0.05)。结论罗哌卡因处理SH-SY5Y细胞能诱发细胞内ROS的蓄积,抑制细胞增殖活性,促进凋亡,p38MAPK通路的激活在诱导凋亡的过程中有重要作用。
Objective To investigate the influence on stress hyPerglycemia and Progrosis of massive area burn injury Patients treated by enteral nutritional emulsion ( TPF-D ) and glutamyl comPound. Methods 44 Patients from January 2013 to February 2015 large area burns in the hosPital were selected and randomly divided into the control grouP and observation grouP, 22 cases in each grouP. Two grouPs of Patients received conventional surgical treatment,on this basis all Patients were given nasogastric tube for enter-al nutrition, the control grouP were given simPle enteral nutrition,the observation grouP added glutamyl comPound. The treatment course was two weeks. Results Before treatment,the fasting Plasma glucose and insulin resistance index had no significant difference between the two grouPs( P 〉 0. 05),a week after treatment and had both imProved after 1 week of treatment,with the observation grouP imProned more than the control grouP ( P 〈 0. 05 );before treatment,the Physical stress indicator i. e. ,the reaction C3,C4,C-reac-tive Protein in both grouPs was no significant difference,and they all deereased;after treatment,with the observation grouP decreased more than the control grouP ( P 〈 0. 05 ) . The adverse reactions were mild in the two grouPs,with no statistically significant difference ( P 〉 0. 05 ) . Conclusion TPF-D and ghctanyl comPound in treating severe burn Patients can effectively imProve fasting Plasma glucose levels,insulin resistance index and reduce body stress indicators C3,C4,C-reactive Protein,has no significant adverse reac-tions,and is worthy of clinical Promotion.
出处
《中国药业》
CAS
2015年第17期13-15,共3页
China Pharmaceuticals